{ "schemaVersion": 2, "eyebrow": "Psychiatry", "title": "Major Depressive Disorder", "summary": "Major depressive disorder requires clinical confirmation after screening, assessment of suicide and bipolar risk, and individualized psychotherapy and medication selection. Use measurement-based follow-up to detect inadequate response, intolerance, or worsening risk early, and escalate care for severe, psychotic, suicidal, or treatment-resistant illness.", "seoDescription": "Evidence-grounded approach to diagnosing, monitoring, and treating major depressive disorder in adults, including safety assessment and treatment resistance.", "clinicalQuestion": "How should physicians confirm, risk-stratify, treat, and monitor adults with major depressive disorder?", "specialty": "Psychiatry", "audience": "U.S. physicians and medical trainees", "tags": [ "major depressive disorder", "depression screening", "PHQ-9", "suicide risk", "measurement-based care", "treatment-resistant depression", "mirtazapine" ], "keyTakeaways": [ "A positive depression screen is not diagnostic; establish a DSM-defined depressive syndrome, assess functional impairment, and evaluate for bipolar disorder, psychosis, substance-related causes, and medical or neurologic contributors. [2][9][17]", "Assess suicidality at presentation and during early treatment or dose changes; urgent psychiatric or emergency evaluation is indicated when risk cannot be safely managed in the outpatient setting. [1][9]", "Psychotherapy and antidepressant medication are effective first-line modalities; selection should account for severity, patient preference, prior response, comorbidity, adverse-effect priorities, access, and safety. [9][10][11][12]", "Use structured symptom and adverse-effect measurement to guide treatment changes. In one randomized trial, measurement-based care accelerated median response from 4 to 2 weeks and remission from 8 to 4 weeks, although applicability to U.S. practice is uncertain. [7]", "Before labeling depression treatment-resistant, verify diagnosis, adherence, tolerability, dose and duration adequacy, ongoing psychosocial or substance-related drivers, and bipolar-spectrum illness. [2][4]" ], "sections": [ { "id": "clinical-assessment", "eyebrow": "Diagnosis", "heading": "Confirm the syndrome and identify conditions that change management", "intro": "Screening identifies risk; clinical assessment establishes diagnosis and immediate treatment setting.", "paragraphs": [ "Major depressive disorder is a clinical diagnosis. Screening instruments can characterize symptom burden and support longitudinal measurement, but a positive result should trigger diagnostic interview, mental status examination, assessment of impairment, treatment planning, and follow-up rather than automatic pharmacotherapy. [9][16]", "A major depressive episode requires a persistent depressed or dysphoric mood with functional interference and at least 5 depressive symptoms over at least 2 weeks; suicidal ideation or attempt is among the symptom domains. [1] The diagnostic interview should establish episode chronology, recurrence, psychotic symptoms, anxiety symptoms, trauma exposure, substance use, medication exposures, and medical or neurologic disease that may account for depressive symptoms. Depression may also occur with bipolar disorder, schizophrenia, neurodegenerative disorders, and Parkinson disease. [17]", "Before antidepressant monotherapy, obtain a focused lifetime history of mania or hypomania and family history of bipolar disorder, depression, and suicide. The mirtazapine label specifically advises bipolar-risk screening because a depressive episode can be the initial presentation of bipolar disorder and antidepressant monotherapy may precipitate mixed or manic illness in susceptible patients. [1]" ], "bullets": [ "Use a validated scale consistently once treatment begins. The PHQ-9 is widely used for depression severity and treatment-response assessment; the QIDS-SR16 and clinician-rated HDRS-17 were used in measurement-based care trials. [9][7]", "Clarify psychotic symptoms, catatonia, severe psychomotor retardation, inability to meet basic needs, and severe agitation because these findings shift urgency and may require specialty or inpatient management. [9]", "For new or disproportionate cognitive symptoms, neurologic findings, late-life onset, or atypical course, evaluate neurologic and medical differentials rather than attributing deficits solely to depression. [17]" ], "subsections": [], "table": { "caption": "Assessment findings that alter the next clinical action. [1][9][17]", "columns": [ "Finding", "Why it matters", "Immediate action" ], "rows": [ [ "Current suicidal ideation, intent, plan, recent attempt, inability to maintain safety", "Risk may escalate before remission and can change during antidepressant initiation or dose adjustment. [1][9]", "Perform a structured safety assessment; arrange emergency or urgent psychiatric evaluation when outpatient safety cannot be assured. [9]" ], [ "Past mania or hypomania, mixed features, bipolar family history", "Antidepressant monotherapy may precipitate mixed or manic illness in susceptible patients. [1]", "Avoid reflex antidepressant monotherapy; obtain psychiatric consultation or manage as bipolar-spectrum illness when indicated. [1]" ], [ "Psychosis, catatonia, severe agitation, profound functional incapacity", "These features indicate severe illness and potential risk to self or others. [9]", "Expedite specialty assessment and determine need for hospital-level care. [9]" ], [ "Cognitive decline, parkinsonism, focal neurologic findings, atypical late presentation", "Depression can be psychiatric, neurologic, or both; neurodegenerative disease is an important differential. [17]", "Pursue targeted medical and neurologic evaluation. [17]" ] ] } }, { "id": "acute-treatment", "eyebrow": "Treatment", "heading": "Select initial treatment by severity, urgency, and patient-specific tradeoffs", "intro": "Use shared decision-making after risk stratification; do not delay urgent stabilization for a prolonged outpatient trial.", "paragraphs": [ "Available evidence supports specific psychotherapies and more than 20 antidepressant medications as first-line treatments for acute depression. [10] The American College of Physicians living guideline addresses both nonpharmacologic and pharmacologic treatment for adults in the acute phase of major depressive disorder. [11][13] For less severe presentations, watchful waiting may be appropriate for selected patients; for more severe symptoms, active treatment is generally indicated. [9]", "Choose psychotherapy, medication, or both according to severity, prior treatment response, adverse-effect vulnerability, patient preference, treatment availability, psychiatric comorbidity, and likelihood of follow-up. [9][10] Medication is not interchangeable with diagnostic reassessment: apparent nonresponse can reflect inadequate exposure, nonadherence, adverse effects, an incorrect diagnosis, unresolved substance use, ongoing psychosocial drivers, or bipolar-spectrum disease. [2][4]", "Escalate urgently for depression with psychosis, severe suicidality, severe psychomotor retardation interfering with activities of daily living, catatonia, or severe agitation. [9] Electroconvulsive therapy is an established somatic treatment in severe depression, and a review cited its association with superior symptomatic and functional change after psychiatric hospitalization; individual indication and risk assessment require specialty management. [17]" ], "bullets": [ "Document baseline severity and functional goals before starting treatment so that response and remission can be distinguished from subjective partial improvement. [7][9]", "Reassess adherence, adverse effects, suicidality, activation, emergent mania, and symptom trajectory early after initiating or changing an antidepressant. [1][9]", "In patients with inadequate response, avoid declaring treatment resistance without documenting adequate prior treatment trials. In FDA development guidance, treatment-resistant depression studies enroll patients who have not responded to more than one prior antidepressant at adequate dose and duration. [2]" ], "subsections": [ { "heading": "Mirtazapine", "paragraphs": [ "Mirtazapine is FDA-indicated for major depressive disorder in adults. The labeled starting dose is 15 mg orally once daily, preferably in the evening; the usual effective range is 15 to 45 mg/day. Do not adjust more often than every 1 to 2 weeks because of its 20- to 40-hour elimination half-life. [1]", "Its H1 antagonism is associated with prominent sedation; antagonism at 5-HT2, 5-HT3, and presynaptic alpha2-adrenergic receptors contributes to its pharmacologic profile. [1] It may be useful when insomnia or reduced appetite are clinically prominent, but weight gain, daytime somnolence, metabolic effects, falls risk, and cognitive impairment can outweigh benefit in some patients. This selection inference is based on labeled adverse-effect patterns rather than comparative-effectiveness evidence. [1]" ], "bullets": [ "Common short-term adverse effects included somnolence (54%), dry mouth (25%), increased appetite (17%), constipation (13%), weight gain (12%), and dizziness (7%) in U.S. controlled trials. [1]", "Monitor weight and metabolic risk when clinically appropriate: increased appetite and at least 7% weight gain occurred more often than with placebo; nonfasting cholesterol and triglyceride elevations were also reported. [1]", "Use caution in older adults and in moderate-to-severe renal or hepatic impairment because clearance is reduced. [1]", "Avoid concomitant psychiatric MAOIs and maintain a 14-day washout in either direction. Do not initiate with linezolid or intravenous methylene blue because of serotonin-syndrome risk. [1]", "Review other serotonergic agents, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's wort; monitor for serotonin syndrome, especially during initiation and titration. [1]", "Counsel regarding alcohol and sedative coexposures because cognitive and motor impairment is additive with alcohol and diazepam. [1]" ] } ], "table": { "caption": "Mirtazapine prescribing and monitoring points from FDA labeling. [1]", "columns": [ "Domain", "Actionable information", "Clinical implication" ], "rows": [ [ "Dose", "Start 15 mg orally once daily, preferably in the evening; effective range 15-45 mg/day; do not change dose at intervals shorter than 1-2 weeks. [1]", "Allow adequate time at each dose before judging response or tolerability. [1]" ], [ "Suicidality", "Monitor all ages for clinical worsening, suicidality, or unusual behavior, particularly during initial months and dose changes. [1]", "Engage family or caregivers when appropriate and prescribe the smallest feasible quantity in patients at overdose risk. [1]" ], [ "Infection symptoms", "Severe neutropenia and agranulocytosis occurred rarely in premarketing trials; discontinue if infection symptoms occur with low white blood cell count. [1]", "Evaluate fever, sore throat, stomatitis, or other infection symptoms promptly. [1]" ], [ "Discontinuation", "Abrupt cessation can cause dizziness, abnormal dreams, paresthesias, agitation, anxiety, fatigue, nausea, vomiting, and sweating. [1]", "Taper gradually over several weeks when feasible. [1]" ], [ "Interactions", "Phenytoin and carbamazepine approximately doubled clearance; cimetidine increased exposure by more than 50%; ketoconazole increased peak level and exposure. [1]", "Review enzyme inducers and inhibitors when efficacy or adverse effects change unexpectedly. [1]" ] ] } }, { "id": "measurement-based-follow-up", "eyebrow": "Monitoring", "heading": "Use measurement-based follow-up to shorten time to treatment adjustment", "intro": "Structured symptom and adverse-effect data should drive decisions, not replace clinical assessment.", "paragraphs": [ "Measurement-based care combines repeated standardized symptom assessment with adverse-effect assessment and a predefined action plan. In a multicenter randomized trial of 154 adults with nonpsychotic MDD, the intervention used the QIDS-SR16 and FIBSER at baseline and weeks 2, 4, 8, 12, and 24 to guide dose adjustment or switching of paroxetine or mirtazapine. [7]", "Compared with clinician-directed standard care, measurement-based care shortened median time to response from 4 to 2 weeks and median time to remission from 8 to 4 weeks; adjusted hazard ratios were 1.53 for response and 1.80 for remission. By week 24, response and remission rates no longer differed significantly. [7] The trial occurred in Pakistan, used only paroxetine and mirtazapine, and included protocol coordinators and more visits in the intervention arm; therefore, it supports structured follow-up but does not establish a U.S.-specific medication algorithm. [7]", "A practical follow-up visit should review score trajectory, functioning, adherence, adverse effects, suicidal thinking or behavior, activation or mania, substance use, psychosocial stressors, and patient priorities. A worsening score or new safety concern requires reassessment of diagnosis, treatment setting, and safety plan rather than simple dose escalation. [1][7][9]" ], "bullets": [ "Define response before treatment: a 50% or greater reduction in a standardized depression score is a commonly used research definition. [4][7]", "Define remission with the instrument being used; in the cited measurement-based trial, HDRS-17 remission was a score of 7 or less. [7]", "Track side-effect burden explicitly. In the trial, a FIBSER total score greater than 4 of 18 indicated poor tolerability requiring dose change or medication switch under the protocol. [7]", "Continue to reassess suicide risk during treatment. Antidepressant labeling identifies early treatment and dose changes as periods requiring close observation. [1]" ], "subsections": [], "table": { "caption": "Measurement-based follow-up framework supported by trial methods and antidepressant labeling. [1][7]", "columns": [ "Visit component", "Measure or question", "Action triggered" ], "rows": [ [ "Depressive symptoms", "Use the same validated scale serially, such as PHQ-9 or QIDS-SR16. [9][7]", "Insufficient improvement should prompt assessment of treatment adequacy, adherence, diagnosis, and treatment modification. [7]" ], [ "Function", "Review work, caregiving, relationships, self-care, and activity goals.", "Persistent functional compromise despite symptom change warrants treatment-plan revision and consideration of psychotherapy, social interventions, or specialty referral. [9]" ], [ "Adverse effects", "Ask specifically about sedation, dizziness, appetite and weight change, gastrointestinal symptoms, activation, sexual effects, and treatment burden. [1][7]", "Adjust dose, timing, agent, or co-medications when tolerability threatens adherence or safety. [1][7]" ], [ "Safety", "Assess suicidal ideation, intent, plan, behavior, access to lethal means, supports, and ability to maintain safety. [1][9]", "Escalate to urgent or emergency psychiatric evaluation when outpatient management is unsafe. [9]" ] ] } }, { "id": "inadequate-response", "eyebrow": "Treatment resistance", "heading": "Approach inadequate response systematically before escalating", "intro": "Incomplete response is common and should trigger a structured reassessment rather than therapeutic drift.", "paragraphs": [ "Treatment-resistant depression lacks a universally accepted clinical cut point; FDA guidance notes that response, partial response, and nonresponse lie on a continuum. For regulatory studies, treatment-resistant depression generally involves failure to respond to more than one prior antidepressant administered at an adequate dose and duration. [2]", "Before changing therapy, verify the original diagnosis and whether the current treatment was delivered adequately. Reassess adherence, tolerability, pharmacokinetic interactions, substance use, bipolar-spectrum symptoms, psychosis, medical and neurologic contributors, and concurrent psychosocial drivers. These steps are particularly important when apparent nonresponse follows low exposure, premature discontinuation, or unrecognized activation. [1][2][17]", "Specialty options may include medication switch, augmentation, structured psychotherapy, transcranial magnetic stimulation, electroconvulsive therapy, or other intervention depending on severity and treatment history. The supplied evidence supports the existence of these modalities but does not provide sufficient contemporary U.S. guideline detail to specify a universal sequencing algorithm. [10][17][22]" ], "bullets": [ "Do not use psilocybin clinically for treatment-resistant depression based on the supplied trial alone. In a phase 2 trial, a single 25-mg synthetic psilocybin dose with psychological support improved week-3 MADRS change versus a 1-mg control by 6.6 points, but sustained response at 12 weeks was not established and suicidal ideation, self-injury, and suicidal behavior occurred. [4]", "The psilocybin trial required antidepressant tapering, preparatory and integration sessions, prolonged monitored administration, and excluded persons at clinically significant suicide risk; results should not be generalized to unsupervised or routine outpatient use. [4]", "When considering pharmacologic augmentation, distinguish FDA-approved adjunctive strategies from off-label approaches and discuss uncertainty, adverse effects, and monitoring burden. A meta-analysis found brexpiprazole adjunctive therapy improved symptom, response, and remission outcomes versus placebo but increased adverse-event discontinuation, akathisia, and weight gain. [19]" ], "subsections": [], "table": { "caption": "High-value reassessment domains in apparent antidepressant nonresponse. [1][2][4][17]", "columns": [ "Domain", "Questions to answer", "Consequence" ], "rows": [ [ "Diagnostic validity", "Is this unipolar MDD, bipolar depression, psychotic depression, substance-related depression, or depression secondary to medical or neurologic disease? [1][17]", "A changed diagnosis changes medication choice, urgency, and specialty referral. [1][17]" ], [ "Treatment adequacy", "Was the drug taken consistently at a therapeutic dose for sufficient duration, with manageable adverse effects? [1][2]", "Correct inadequate exposure before declaring resistance. [1][2]" ], [ "Safety and acuity", "Has suicidality, psychosis, catatonia, agitation, or inability to function emerged? [9]", "Move to urgent specialty or inpatient evaluation when indicated. [9]" ], [ "Advanced intervention", "Is there persistent disabling illness despite adequate trials, or need for rapid definitive symptom control? [17]", "Refer for specialty evaluation of somatic and augmentation options. [17][22]" ] ] } } ], "faq": [ { "question": "Is a positive PHQ-9 sufficient to diagnose major depressive disorder?", "answer": "No. The PHQ-9 is useful for screening and serial severity measurement, but diagnosis requires clinical assessment of depressive syndrome, impairment, differential diagnosis, bipolar risk, and safety. [9][1]" }, { "question": "When should an antidepressant be changed for nonresponse?", "answer": "Do not rely on a single calendar threshold alone. Confirm adherence, dose and duration adequacy, adverse effects, interactions, diagnosis, bipolar-spectrum symptoms, substance use, and safety; then modify treatment using serial symptom measurement. [1][2][7]" }, { "question": "What monitoring is required after starting mirtazapine?", "answer": "Monitor early for worsening depression, suicidality, unusual behavioral change, activation or mania, sedation, dizziness, appetite or weight gain, metabolic effects, and infection symptoms suggestive of neutropenia. Review serotonergic drugs, MAOIs, alcohol, sedatives, and enzyme modifiers. [1]" }, { "question": "Does psilocybin have an established role in treatment-resistant depression?", "answer": "Not from the supplied evidence. A phase 2 trial found a week-3 benefit for a monitored 25-mg synthetic psilocybin session with psychological support, but durability was uncertain and serious suicidal events occurred; larger comparative studies were deemed necessary. [4]" } ], "references": [ { "number": 1, "title": "479 Mirtazapine 15 mg\n \n \n Mirtazapine Tablets, USP", "detail": "www.dailymed.nlm.nih.gov", "url": "https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5a1ce60e-977b-1801-e053-2a91aa0adb5e&type=display", "authors": "www.dailymed.nlm.nih.gov", "host": "www.dailymed.nlm.nih.gov" }, { "number": 2, "title": "Major Depressive Disorder: Developing Drugs for Treatment", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/113988/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 3, "title": "Major Depressive Disorder: Developing Drugs for Treatment | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 4, "title": "Single-Dose Psilocybin for a Treatment-Resistant Episode ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206443", "authors": "www.nejm.org", "host": "www.nejm.org" }, { "number": 5, "title": "The Medical Management of Depression", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/abs/10.1056/NEJMra050730", "authors": "www.nejm.org", "host": "www.nejm.org" }, { "number": 6, "title": "Medical conditions and the risk of subsequent major ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00073-8/fulltext", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 7, "title": "Measurement-Based Care to Enhance Antidepressant Treatment Outcomes in Major Depressive Disorder: A Randomized", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838317", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 8, "title": "Persistent depressive disorder - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/805", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 9, "title": "Depression in adults - Symptoms, diagnosis and treatment", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/55", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 10, "title": "Management of Depression in Adults: A Review", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jama/article-abstract/2819714", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 11, "title": "Nonpharmacologic and Pharmacologic Treatments of Adult ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M22-1845", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 12, "title": "The Management of Major Depressive Disorder", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/pdf/10.7326/M22-1603", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 13, "title": "A Clinical Practice Guideline From the American College of ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M15-2570", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 14, "title": "The Management of Major Depressive Disorder: Synopsis ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/abs/10.7326/m22-1603", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 15, "title": "The Generic Wellbutrin Problem: Whose Fault Is It?", "detail": "www.science.org", "url": "https://www.science.org/content/blog-post/generic-wellbutrin-problem-whose-fault-it", "authors": "www.science.org", "host": "www.science.org" }, { "number": 16, "title": "Improving Depression Management in Primary Care : Journal of Christian Nursing", "detail": "journals.lww.com", "url": "https://journals.lww.com/journalofchristiannursing/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005217-202604000-00011", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 17, "title": "Depression", "detail": "journals.lww.com", "url": "https://journals.lww.com/continuum/fulltext/2015/06000/depression.17.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 18, "title": "Impact of the 2004 Food and Drug Administration... : Medical Care", "detail": "journals.lww.com", "url": "https://journals.lww.com/lww-medicalcare/fulltext/2010/11000/impact_of_the_2004_food_and_drug_administration.3.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 19, "title": "Adjunctive Brexpiprazole as a Novel Effective... : Journal of Clinical Psychopharmacology", "detail": "journals.lww.com", "url": "https://journals.lww.com/psychopharmacology/_layouts/15/oaks.journals/downloadpdf.aspx?an=00004714-201702000-00011", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 20, "title": "Updated guideline on managing depression in adults", "detail": "wchh.onlinelibrary.wiley.com", "url": "https://wchh.onlinelibrary.wiley.com/doi/10.1002/psb.2017", "authors": "wchh.onlinelibrary.wiley.com", "host": "wchh.onlinelibrary.wiley.com" }, { "number": 21, "title": "Biomarker for Diagnosis and Monitoring of Treatment ...", "detail": "analyticalsciencejournals.onlinelibrary.wiley.com", "url": "https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bmc.70197", "authors": "analyticalsciencejournals.onlinelibrary.wiley.com", "host": "analyticalsciencejournals.onlinelibrary.wiley.com" }, { "number": 22, "title": "Pharmacological Augmentation in Unipolar Depression", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/23/9/587/5836840", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 23, "title": "Changes in Prescription Habits with the Introduction of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/milmed/article-pdf/173/1/100/23663934/milmed.173.1.100.pdf", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 24, "title": "Off-label policy through the lens of trazodone usage and spending in the United States", "detail": "academic.oup.com", "url": "https://academic.oup.com/healthaffairsscholar/article/3/7/qxaf114/8160304", "authors": "academic.oup.com", "host": "academic.oup.com" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "479 Mirtazapine 15 mg\n \n \n Mirtazapine Tablets, USP", "detail": "www.dailymed.nlm.nih.gov", "url": "https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5a1ce60e-977b-1801-e053-2a91aa0adb5e&type=display", "authors": "www.dailymed.nlm.nih.gov", "host": "www.dailymed.nlm.nih.gov", "snippet": "The efficacy of mirtazapine tablets, USP in maintaining a response in patients with major depressive disorder for up to 40 weeks following 8 to 12 weeks of initial open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use mirtazapine tablets, ", "score": 0.15575814 }, { "number": 2, "title": "Major Depressive Disorder: Developing Drugs for Treatment", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/113988/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "Drugs for Treatment 3 Guidance for Industry1 4 5 6 7 8 This draft guidance, when finalized, will represent the current thinking of the Food and Drug 9 Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not 10 binding on FDA or the public. You can use", "score": 0.42677602 }, { "number": 3, "title": "Major Depressive Disorder: Developing Drugs for Treatment | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "Search for FDA \nGuidance Documents\n\nThe purpose of this guidance is to assist sponsors in the clinical development of drugs for the monotherapeutic, combination, and adjunctive treatment of major depressive disorder (MDD). Specifically, this guidance addresses the FDA’s current thinking regarding ", "score": 0.32562825 }, { "number": 4, "title": "Single-Dose Psilocybin for a Treatment-Resistant Episode ...", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206443", "authors": "www.nejm.org", "host": "www.nejm.org", "snippet": "| Median | 5.0 | 4.0 | 4.0 | 5.0 |\n| Duration of current depressive episode — no. (%) | | | | |\n| <1 yr | 12 (15) | 10 (13) | 10 (13) | 32 (14) |\n| 1 yr to <2 yr | 33 (42) | 28 (37) | 33 (42) | 94 (40) |\n| ≥2 yr | 34 (43) | 37 (49) | 36 (46) | 107 (46) |\n| Failed treatments for current depressiv", "score": 0.20972891 }, { "number": 5, "title": "The Medical Management of Depression", "detail": "www.nejm.org", "url": "https://www.nejm.org/doi/abs/10.1056/NEJMra050730", "authors": "www.nejm.org", "host": "www.nejm.org", "snippet": "by JJ Mann · 2005 · Cited by 693 — Major depression, which affects 5 to 13 percent of medical outpatients, is often undiagnosed and untreated. Treatment with antidepressant and", "score": 0.1711723 }, { "number": 6, "title": "Medical conditions and the risk of subsequent major ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00073-8/fulltext", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "by PE Sigvardsen · 2025 · Cited by 16 — The absolute risk for major depressive disorder 20 years after onset of a medical condition was 18·9% (18·8–19·0) in men and 24·4% (24·3–24·5)", "score": 0.2233944 }, { "number": 7, "title": "Measurement-Based Care to Enhance Antidepressant Treatment Outcomes in Major Depressive Disorder: A Randomized", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838317", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Visual Abstract.\n\n guides clinical decisions through structured monitoring of symptoms and adverse effects. Although MBC has been associated with improved outcomes in major depressive disorder (MDD), its effectiveness in low- and middle-income countries (LMICs) remains understudied.\n\nObjectiveTo ass", "score": 0.5163278 }, { "number": 8, "title": "Persistent depressive disorder - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/805", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : mise à jour des lignes directrices ", "score": 0.5021246 }, { "number": 9, "title": "Depression in adults - Symptoms, diagnosis and treatment", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/55", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "### References\n\n#### Key articles\n\nAmerican Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.\n\nNational Institute for Health and Care Excellence. Depression in adults: treatment an", "score": 0.42076674 }, { "number": 10, "title": "Management of Depression in Adults: A Review", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jama/article-abstract/2819714", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "by GE Simon · 2024 · Cited by 264 — Effective first-line depression treatments include specific forms of psychotherapy and more than 20 antidepressant medications. Close", "score": 0.17188005 }, { "number": 11, "title": "Nonpharmacologic and Pharmacologic Treatments of Adult ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M22-1845", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by G Gartlehner · 2023 · Cited by 59 — Practice Guideline for the Treatment of Patients with Major Depressive Disorder. The Management of Major Depressive Disorder. VA/DoD Clinical", "score": 0.66308063 }, { "number": 12, "title": "The Management of Major Depressive Disorder", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/pdf/10.7326/M22-1603", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by JR McQuaid · 2022 · Cited by 60 — This article describes key updates to the guide- lines for managing depression, which include recommen- dations for screening, monitoring, ...Read more", "score": 0.6030211 }, { "number": 13, "title": "A Clinical Practice Guideline From the American College of ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M15-2570", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by A Qaseem · 2016 · Cited by 372 — Various treatment approaches can be used to manage MDD, such as psychotherapy, complementary and alternative medicine (CAM), exercise, and ...Read more", "score": 0.5391051 }, { "number": 14, "title": "The Management of Major Depressive Disorder: Synopsis ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/abs/10.7326/m22-1603", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by JR McQuaid · 2022 · Cited by 56 — Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the ...Read more", "score": 0.51325434 }, { "number": 15, "title": "The Generic Wellbutrin Problem: Whose Fault Is It?", "detail": "www.science.org", "url": "https://www.science.org/content/blog-post/generic-wellbutrin-problem-whose-fault-it", "authors": "www.science.org", "host": "www.science.org", "snippet": "> _The FDA considers the generic form of bupropion XL 300 mg (Teva Pharmaceuticals) bioequivalent and therapeutically equivalent to (interchangeable with) Wellbutrin XL 300 mg. Although there are small differences in the pharmacokinetic profiles of these two formulations, they are not outside the es", "score": 0.21255913 }, { "number": 16, "title": "Improving Depression Management in Primary Care : Journal of Christian Nursing", "detail": "journals.lww.com", "url": "https://journals.lww.com/journalofchristiannursing/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005217-202604000-00011", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Qaseem A., Owens D. K., Etxeandia-Ikobaltzeta I., Tufte J., Cross J. T., Wilt T. J., Crandall C. J., Balk E., Cooney T. G., Fitterman N., Hicks L. A., Lin J. S., Maroto M., Obley A. J., Tice J. A., Yost J; Clinical Guidelines Committee of the American College of Physicians. (2023). Nonpharmacologic ", "score": 0.7004242 }, { "number": 17, "title": "Depression", "detail": "journals.lww.com", "url": "https://journals.lww.com/continuum/fulltext/2015/06000/depression.17.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Google Scholar\n\n19.\n\nAmerican Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorders. 3rd ed. Arlington, VA: American Psychiatric Association, 2010.\n\nGoogle Scholar\n\n20.\n\nKendrick T, Peveler R. Guidelines for the management of depression: NICE work", "score": 0.53954184 }, { "number": 18, "title": "Impact of the 2004 Food and Drug Administration... : Medical Care", "detail": "journals.lww.com", "url": "https://journals.lww.com/lww-medicalcare/fulltext/2010/11000/impact_of_the_2004_food_and_drug_administration.3.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "and specifically major depressive disorder (MDD) (N = 11,532). [...] ## Results:\n\nCompared to youth with a new-onset diagnosis of depression in the pre-FDA warning period, youth with new-onset diagnosis of depression during the postwarning period had (1) A significantly lower likelihood of antidepre", "score": 0.122491956 }, { "number": 19, "title": "Adjunctive Brexpiprazole as a Novel Effective... : Journal of Clinical Psychopharmacology", "detail": "journals.lww.com", "url": "https://journals.lww.com/psychopharmacology/_layouts/15/oaks.journals/downloadpdf.aspx?an=00004714-201702000-00011", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Advertisement\n\nOvid® Ovid Logo\n\nSearch Ovid Search Ovid\n\nBrowse Browse\n\nLogin Login\n\nJournal of Clinical Psychopharmacology\n\nNavbar\n\nMenu\n\n Issues \n Media \n About Journal \n For Authors \n\n More menu items \n\nSearch Journal Search Journal\n\nButton group.\n\n Check Access \n Image 1", "score": 0.09302524 }, { "number": 20, "title": "Updated guideline on managing depression in adults", "detail": "wchh.onlinelibrary.wiley.com", "url": "https://wchh.onlinelibrary.wiley.com/doi/10.1002/psb.2017", "authors": "wchh.onlinelibrary.wiley.com", "host": "wchh.onlinelibrary.wiley.com", "snippet": "Lithium treatment requires monitoring weight, renal and thyroid function and calcium levels before and every six months during treatment.", "score": 0.5310884 }, { "number": 21, "title": "Biomarker for Diagnosis and Monitoring of Treatment ...", "detail": "analyticalsciencejournals.onlinelibrary.wiley.com", "url": "https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bmc.70197", "authors": "analyticalsciencejournals.onlinelibrary.wiley.com", "host": "analyticalsciencejournals.onlinelibrary.wiley.com", "snippet": "by S Lee · 2025 · Cited by 2 — To control the high heterogeneity of MDD, a pairwise design in which depressed and remitted states of the same patient were paired to minimize ...Read more", "score": 0.35824135 }, { "number": 22, "title": "Pharmacological Augmentation in Unipolar Depression", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/23/9/587/5836840", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by RW Taylor · 2020 · Cited by 94 — Pharmacological augmentation is a recommended strategy for patients with treatment-resistant depression. See guidelines for recommendations in cases of hepatic", "score": 0.23351443 }, { "number": 23, "title": "Changes in Prescription Habits with the Introduction of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/milmed/article-pdf/173/1/100/23663934/milmed.173.1.100.pdf", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by R McLay · 2008 · Cited by 6 — There are currently five selective serotonin reuptake inhibi- tors (SSRIs) with Food and Drug Administration (FDA) approval in the treatment of depression:", "score": 0.14585622 }, { "number": 24, "title": "Off-label policy through the lens of trazodone usage and spending in the United States", "detail": "academic.oup.com", "url": "https://academic.oup.com/healthaffairsscholar/article/3/7/qxaf114/8160304", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "## Examining off-label use via an analysis of trazodone\n\nThis article examines off-label utilization and spending on trazodone, a serotonin receptor antagonist and reuptake inhibitor that is FDA approved for the treatment of patients with major depressive disorder. We analyzed trazodone as a case st", "score": 0.12939197 } ], "publishedAt": "2026-08-21T00:12:05.277698Z", "updatedAt": "2026-08-21T00:12:05.277698Z", "readingMinutes": 7, "slug": "major-depressive-disorder" }